Mer­ck KGaA rais­es aware­ness for smol­der­ing MS symp­toms that cause pa­tients to 'un­rav­el'

Re­cent ev­i­dence sug­gests re­duc­ing re­laps­es is “on­ly part of [the] bat­tle” for mul­ti­ple scle­ro­sis pa­tients, ac­cord­ing to Mer­ck KGaA.

While it was pre­vi­ous­ly thought that MS pa­tients go in­to pe­ri­ods of re­mis­sion, sci­ence now points to some pa­tients ex­pe­ri­enc­ing grad­ual neu­rode­gen­er­a­tion from the start, caus­ing them to sub­tly wors­en de­spite no signs of re­lapse. Mer­ck KGaA’s EMD Serono wants to dri­ve aware­ness to the con­di­tion, called “smol­der­ing MS,” as it ad­vances its late-stage BTK in­hibitor evo­bru­ti­nib in re­laps­ing MS.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.